- BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q4 GAAP EPS of $0.00 beats by $0.07 .
- Revenue of $537.5M (+19.5% Y/Y) misses by $0.74M .
- Non-GAAP Income increased to $67.4 million for the fourth quarter of 2022 compared to Non-GAAP Income of $7.1 million for the same period in 2021
- In 2023, More than 15% Growth in Total Revenues and Approximately 30% Growth in Net Income Expected Based on Mid-point of Today's Full-year Guidance; VOXZOGO Revenues Expected to More than Double
- ROCTAVIAN European Commercial Launch and U.S. Launch Preparations Both Underway; 3-year Analysis from Phase 3 ROCTAVIAN Study in Adults with Severe Hemophilia A Recently Submitted to the FDA
For further details see:
BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M